Analysts’ Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Inotiv (NOTV)
TipRanks (Tue, 13-Jan 10:20 AM ET)
Globe Newswire (Tue, 13-Jan 9:15 AM ET)
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
Globe Newswire (Thu, 11-Dec 9:00 AM ET)
Globe Newswire (Wed, 3-Dec 4:05 PM ET)
Globe Newswire (Tue, 25-Nov 7:00 AM ET)
Globe Newswire (Fri, 21-Nov 7:00 AM ET)
NOTV Projects Strong Q4 Revenue and Growing DSA Backlog—Book-to-Bill Ratios Remain Above 1.0
Market Chameleon (Tue, 18-Nov 6:44 AM ET)
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Globe Newswire (Mon, 17-Nov 4:05 PM ET)
Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire (Fri, 24-Oct 10:20 AM ET)
Inotiv, Inc. to Participate in Three Investor Conferences in November 2025
Globe Newswire (Tue, 21-Oct 4:05 PM ET)
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Inotiv trades on the NASDAQ stock market under the symbol NOTV.
As of January 14, 2026, NOTV stock price climbed to $0.61 with 163,293 million shares trading.
NOTV has a beta of 0.62, meaning it tends to be less sensitive to market movements. NOTV has a correlation of 0.01 to the broad based SPY ETF.
NOTV has a market cap of $20.89 million. This is considered a Sub-Micro Cap stock.
Last quarter Inotiv reported $138 million in Revenue and -$.25 earnings per share. This beat revenue expectation by $642,000 and missed earnings estimates by -$.17.
In the last 3 years, NOTV traded as high as $11.42 and as low as $.47.
The top ETF exchange traded funds that NOTV belongs to (by Net Assets): VTI, VXF, PRFZ, IWC.
NOTV has underperformed the market in the last year with a return of -85.6%, while the SPY ETF gained +20.0%. In the last 3 month period, NOTV fell short of the market, returning -55.6%, while SPY returned +4.4%. However, in the most recent 2 weeks NOTV has outperformed the stock market by returning +11.3%, while SPY returned +0.5%.
NOTV support price is $.56 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NOTV shares will trade within this expected range on the day.